Close

Please fill all fields and submit the form.

Name:
Email:

Phone:

Notes:



Close

Please fill out all fields in the form. Please be as detailed as possible. We will respond with pricing and availability within 1-2 business days.

Name:
Company/Institution:

Phone:
Email:

Disease:

Organ/Tissue type:

Format:

Number of patients/donors required for the study:

Clinical Specifications:

Applications/Research topic:

New GPCR Cell Lines and Activity Assays

01/08/2013

Capital Biosciences is pleased to announce that it can now offer a number of ready-to-use stable cell lines expressing G-protein coupled receptors (GPCR) or cyclic nucleotide phosphodiesterases (PDEs) as usefull tools for drug screening. In addition reliable assays for GPCR or PDE activity based on ACTOne technology are also available.

Advantages of ACTOne Technology as the key platform used for the development of Cell Based Assay for GPCR and PDE:

  • Use of a modified cyclic nucleotide-gated (CNG) ion channel as a biosensor
  • Ultrasensitive response to cAMP fluctuations
  • Suitable for high-throughput screening of GPCR-target molecules in living cells
  • Companion assay kits available for easy use
  • Cost effective system for drug discovery and other related studies

Commercial licensing for use of these cell lines in large scale screening of potential dug candidates is also available.